期刊文献+

三维适形放疗联合卡培他滨治疗局部晚期胰腺癌

Treatment of local advanced pancreatic carcinoma with three dimensional conformal radiotherapy combined with capecitabine
原文传递
导出
摘要 目的评价三维适形放疗联合卡培他滨治疗局部晚期胰腺癌的疗效。方法47例胰腺癌患者分为卡培他滨+三维适形放疗(综合组,25例)和单纯三维适形放疗(单放组,22例),比较疼痛缓解率、近期疗效及生存率。结果综合组和单放组疼痛缓解率分别为80%和65%,近期有效率分别为76%和59%。综合组1、2年生存率分别为64%、16%,显著高于单放组的45.5%、9.1%(P<0.05)。主要毒副反应为1~2级消化道反应及1~3级血液毒性。结论三维适形放疗联合卡培他滨治疗局部晚期胰腺癌,副反应较轻,能改善患者的生存质量,延长生存期。 Objective To evaluate therapeutic effect of three-dimensional eonformal radiotherapy (3DCRT) combined with capecitabine on the local advanced pancreatic carcinoma. Methods Foutty-seven patients with pancreatic carcinoma were divided into group A treated with capeeitabine combined with 3DCRT in 25 cases and group B treated with 3DCRT alone in 22 eases. Pain remission rate, short term efficiency and survival rate were compared between two groups. Results Pain remission rate was 80% for group A and 65% for group B. Short term effective rate was 76% for group A and 59% for group B. The 1- and 2-year survival rates were 64% and 16% in group A,whieh were significantly higher than 45.5% and 9.1% in group B (P〈0.05). Main toxic and side effects were digestive tract reaction ( Ⅰ - Ⅱ grade) and blood toxicity ( Ⅰ - Ⅲ grade). Conclusion Treatment of local advanced pancreatic carcinoma with 3DCRT combined with capeeitabine can improve the life quality and prolong the survival rate with slight side effects.
出处 《江苏医药》 CAS CSCD 北大核心 2009年第7期764-766,共3页 Jiangsu Medical Journal
关键词 胰腺癌 适形放疗 卡培他滨 同期放化疗 Pancreatic carcinoma Three-dimensional conformal radiotherapy Capecitabine Concurrent chemoradiotherapy
  • 相关文献

参考文献6

二级参考文献42

  • 1上海市肿瘤研究所流行病室.1995年上海肿瘤发病率报道.肿瘤,1998,18(3):1-2.
  • 2[2]Laack E,Mende T,Durk H, et al . Gemcitabine vinorelbine and cisplatin combination chemotherapy in advanced non - smallcell lung cancer. a phase Ⅱ trial[T].Cancer, 2002,38: 554 ~ 560.
  • 3[3]Salman H S, Tanaka Ksparano J A. Phase Ⅰ / Ⅱtrial of gemcitabine plus cyclophphamide inpatients with metastatic breast carcinoma previously treated with taxanes [J]. Clin Breast Cancer, 2002,229 ~ 303.
  • 4[4]D' Agostion G, Ferradina G, Garganese aaga, et al . phase Ⅰ study of gemcitabine and liposomal Doxorubicin in relapsed ovarian cancer[J]. Oncology, 2002,62:110~ 114.
  • 5Burris H, Moore M, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first - line therapy for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Oncol, 1997, 5:2403 -2413.
  • 6Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2. 0. An improved reference for grading the acute effects of cancer treatment : impact on radiotherapy [ J ]. Int J Radiat Oncol Biol Phys, 2000, 47( 1 ) :13 -47.
  • 7Katz A, Hanlon A, Lanciano R, et al. Prognostic value of CA19 -9 levels in patients with carcinoma of the pancreas treated with radiotherapy [J]. Int J Radiat Oncol Biol Phys, 1998, 41 (2) : 393 - 396.
  • 8Rich TA. Chemoradiation for pancreatic and biliary cancer: current status of RTOG studies [ J]. Ann Oncol, 1999, 10 ( Suppl4 ) :231- 233.
  • 9Ishii H, Okada S, Tokuuye K, et al. Protracted 5 - fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma [ J ]. Cancer, 1997, 79 ( 8 ) : 1516- 1520.
  • 10Niederhuber J, Brennan M, Menck H. The national cancer database report on pancreatic cancer[ J ]. Cancer, 1995, 76A : 1671 - 1677.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部